GSK says court has dismissed all cases alleging five remaining cancers in MDL
The Fly

GSK says court has dismissed all cases alleging five remaining cancers in MDL

In response to yesterday’s court ruling in the Zantac federal Multi-District Litigation, or MDL, in the U.S., GSK plc issued the following statement: "GSK welcomes yesterday’s ruling by the MDL Court. Following the 12 epidemiological studies conducted looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer. Yesterday’s ruling reflects the state of that science and ensured that unreliable and litigation-driven science did not enter the federal courtroom. In excluding plaintiffs’ epidemiological evidence and expert testimony based on their deficiencies and unreliability, the Court has dismissed all MDL cases alleging the five remaining cancers in the MDL – liver, bladder, pancreatic, esophageal, and stomach. GSK will continue to defend itself vigorously, including against all claims brought at the state level."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on GSK:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App